PDA

View Full Version : Positive interim results of ARRY-380 in Phase 1 trial announced


News
12-13-2009, 09:50 PM
Array BioPharma Inc. today announced positive interim results of its novel, small molecule HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in advanced cancer patients.

More... (http://www.news-medical.net/news/20091213/Positive-interim-results-of-ARRY-380-in-Phase-1-trial-announced.aspx)